Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases

Table 1 Disease activity index evaluation according to Mayo score

	Stool frequency	Mucosal appearance	Rectal bleeding	Physician’s overall assessment of disease severity
0	Normal number of stools for the patient	Normal	None	Normal
1	1-2 stools/d more than normal	Mild friability	Streaks of blood	Mild
2	3-4 stools/d more than normal	Moderate friability	Obvious blood	Moderate
3	5 or more stools/d more than normal	Exudation, spontaneous bleeding	Mostly blood	Severe

Score subtotal on the left column.

Table 2 Features of patients enrolled into the study

Patients features	All	UC	CD
No. of patients	14	10	4
Sex (F/M)	5/9	5/5	0/4
Age (yr), mean ± SD	49.4 ± 17.7	54.9 ± 17.5	34.7 ± 7.6
Disease duration at enrollment (yr), mean ± SD	4.8 ± 3.1	4.9 ± 3.1	4.5 ± 3.7
Diagnosis
Pancolitis	8	-	-
Distal colitis	2	-	-
Colonic CD	4	-	-
DAI at time of enrollment, median ± SE	7 ± 4	6.5 ± 5	7 ± 2
DAI after the treatment, median ± SE	2 ± 2	2 ± 2	1.5 ± 2
HI at time of enrollment, median ± SE	1 ± 1	1 ± 1	1.5 ± 1
HI after the treatment, median ± SE	0.5 ± 1	0.5 ± 1	0.5 ± 1
DAI at time of enrollment, mean ± SD	6.6 ± 2.4	6.6 ± 2.7	6.5 ± 1.7
DAI after treatment, mean ± SD	1.9 ± 1.5	2.0 ± 1.6	1.5 ± 1.3
HI at time of enrollment, mean ± SD	1.4 ± 0.5	1.4 ± 0.5	1.5 ± 0.6
HI after treatment, mean ± SD	0.5 ± 0.5	0.5 ± 0.5	0.5 ± 0.6
Time between 1st and 2nd colonoscopy (wk), mean ± SD	4.7 ± 4	5.1 ± 4.6	3 ± 2.8
Other therapy (n)
Mesalazine	6	5	1
AZA	3	1	2
Deflazacort	1	1	0
No other therapy	4	3	1

AZA: Azathioprine; F: Female; M: Male; UC: Ulcerative colitis; CD: Crohn’s disease; DAI: Disease activity index; HI: Histological index.